acute pericarditis
in review
5 min read
Updated 2026-10-21
acute pericarditis
Pleuritic, positional chest pain + rub, PR depression/diffuse ST elevation, raised CRP or new effusion. Most cases are viral/idiopathic and managed as outpatients with high-dose ASA or NSAID (+ PPI) for 1–2 weeks, then taper, plus colchicine for ≥3 months, and exercise restriction until remission. Admit if fever, subacute onset, large effusion/tamponade, NSAID failure, myocarditis, immunosuppression, trauma or anticoagulation. Corticosteroids are second line — high doses and fast tapers drive recurrence.
mechanism → management
- Inflammation of the pericardial layers → friction (rub), irritation of adjacent epicardium (diffuse ST elevation, PR depression), exudate (effusion), CRP rise
- Colchicine blocks neutrophil microtubules and NLRP3 inflammasome → IL-1β ↓ → halves recurrences on top of ASA/NSAID (ICAP (2013))
- Recurrent pericarditis is autoinflammatory (IL-1–driven) → anti-IL-1 agents work and allow steroid withdrawal
- Corticosteroids suppress acutely but high doses with fast tapers predispose to recurrence and chronic course; recurrences cluster below prednisone ~15 mg/day → steroids last, low dose, slow taper
- Troponin rise = myocardial involvement (myopericarditis) → same treatment (NSAID + PPI and colchicine both IIa), but exercise restriction and imaging matter more; new LV dysfunction = perimyocarditis → manage as myocarditis
- Tachycardia aggravates inflammation → beta-blocker helps if HR >75 and symptoms persist despite full anti-inflammatory therapy (IIa)
diagnosis
| Element | Finding |
|---|---|
| clinical presentation | pleuritic and/or positional chest pain (>80%) — better sitting forward |
| rub | superficial scratchy sound (≤33%) |
| ECG | widespread concave ST elevation, PR depression — the pericardium is electrically silent, so ECG change implies epicardial myocardial inflammation → look for myocarditis |
| biomarker | ↑ CRP |
| imaging | new or worsening effusion; pericardial oedema/LGE on CMR |
- ESC 2025: definite = presentation + >1 additional criterion; possible = presentation + 1
- Bedside shortcut: the classic ≥2 of 4 (pericardial pain, rub, ECG changes, new/worsening effusion) still works — ESC 2025 keeps the same elements and adds CRP and CMR as criteria
- Baseline workup in all: ECG, CXR, CBC, CRP, troponin, renal/liver function, TTE (normal in 40–50% of first episodes)
- CMR when the diagnosis is uncertain, myocardial involvement suspected, or recurrent/incessant course (I)
- Exclude ACS when suspected (angiography or CTCA by likelihood)
- Routine viral serology not useful (except HIV, hepatitis C, Lyme where relevant)
admit (high-risk features)
| Major (validated) | Minor |
|---|---|
| fever >38°C | myopericarditis |
| subacute onset | immunosuppression |
| large effusion (>20 mm) or tamponade | trauma |
| no response to ASA/NSAID after ≥1 week | oral anticoagulation |
Any feature → admit and search for a non-viral cause (TB, malignancy, autoimmune, bacterial). None → outpatient; reassess response at 1–2 weeks.
treatment
| Drug | Dose | Duration |
|---|---|---|
| ASA (first choice post-MI or already on antiplatelet; CAD) | 750–1000 mg TID | 1–2 weeks, then ↓ 250 mg every 1–2 weeks |
| ibuprofen | 600–800 mg TID | 1–2 weeks, then ↓ 200 mg every 1–2 weeks |
| indomethacin (usually recurrent/incessant) | 25–50 mg TID | 1–2 weeks, then ↓ 25 mg every 1–2 weeks |
| colchicine | 0.5 mg BID; 0.5 mg daily if <70 kg or severe renal impairment | ≥3 months first episode, ≥6 months recurrent; no taper needed |
| prednisone (second line) | 0.2–0.5 mg/kg/day | 2–4 weeks, slow taper over months |
- PPI with every ASA/NSAID course
- Taper only once asymptomatic and CRP normal; full dose until then
- Renal impairment → adjust NSAID dose or use low-dose steroid; elderly → halve colchicine in some
- Exercise restriction until remission (symptoms, CRP, ECG/imaging normal), at least 1 month — athletes and non-athletes (I)
- Steroids first-line only with a specific reason: systemic inflammatory disease already on steroids, post-pericardiotomy, post-vaccine, severe CKD, NSAID-interacting drugs such as OAC
- Steroid starting doses >25 mg/day only for a few days. Tapering steps: 25–15 mg → 2.5 mg every 2–4 weeks; <15 mg → 1.25–2.5 mg every 2–6 weeks
- Long-term steroid → calcium + vitamin D; bisphosphonate if ≥5–7.5 mg/day long term in men ≥50 and postmenopausal women
recurrent and incessant pericarditis
- Recurrent = new symptoms after remission; incessant = no symptom-free interval >4 weeks despite full therapy
- Usual course: remission in 4–6 weeks. Recurrence in 20–30% without colchicine; ~10% incessant (can progress to constriction within months — very rare in idiopathic recurrent disease)
- Recurrence on steroid taper → don’t increase the steroid: keep colchicine, add an NSAID
- Anti-IL-1 — anakinra 1–2 mg/kg/day (max 100 mg) (AIRTRIP (2016)) or rilonacept 320 mg load then 160 mg weekly (RHAPSODY (2021); not marketed in Europe) — after failure of first-line therapy and steroids with ↑ CRP (I A); also if CMR shows pericardial inflammation regardless of CRP (IIa). Continue ≥6 months, slow taper; mild infection risk
- Then: hydroxychloroquine (IIb), azathioprine (steroid-sparing), IVIG
- Colchicine is the last drug withdrawn, after stable remission
- Refractory to steroids and anti-IL-1 → hydroxychloroquine may be considered (IIb)
- Refractory despite all therapy → pericardiectomy considered
special settings
| Setting | Approach |
|---|---|
| post-MI pericarditis | high-dose ASA first choice (I); avoid other NSAIDs and steroids → STEMI management |
| post-cardiac injury (post-pericardiotomy, post-procedural; post-MI as above) | anti-inflammatory therapy (I); anti-IL-1 if refractory; follow for constriction. Colchicine started 48–72 h before cardiac surgery × 1 month ↓ post-pericardiotomy syndrome (IIa) |
| pregnancy | NSAIDs only until week 20; pre-conception counselling if recurrent → heart disease in pregnancy |
| immune checkpoint inhibitors | myopericarditis → immune checkpoint inhibitor toxicity |
| tamponade, constriction, effusion | → pericardial effusion, tamponade and constriction |
Prepared 2026-10-21. Not yet verified — check every number against the sources.